Legend Biotech (LEGN) Asset Writedowns and Impairment (2023 - 2026)

Legend Biotech (LEGN) has 5 years of Asset Writedowns and Impairment data on file, last reported at $865000.0 in Q3 2025.

• Quarterly Asset Writedowns and Impairment rose 114.64% year-over-year to $865000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$5.3 million (down 754.17% YoY) and the FY2024 annual result came in at $4.4 million, changed N/A from the prior year.
• Asset Writedowns and Impairment improved to $865000.0 in Q3 2025, from -$3.8 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $1.8 million in Q1 2024 to a low of -$3.8 million in Q1 2025.
• A 4-year average of -$288909.1 and a median of $226000.0 in 2023 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2021 — Asset Writedowns and Impairment jumped 650.0% — and 2025, when it sank 316.16%.
• Tracing LEGN's Asset Writedowns and Impairment over 4 years: stood at $22000.0 in 2021, then slumped by 6209.09% to -$1.3 million in 2023, then slumped by 78.94% to -$2.4 million in 2024, then jumped by 135.97% to $865000.0 in 2025.
• The last three Asset Writedowns and Impairment figures came in at $865000.0 (Q3 2025), -$3.8 million (Q1 2025), and -$2.4 million (Q4 2024), per Business Quant data.